- SK pharmteco has expanded stability storage capacity by 40% at its El Dorado Hills, California, facility.
- The upgrade supports increased demand for drug substance and drug product stability studies under CGMP conditions.
SK pharmteco, a global contract development and manufacturing organisation (CDMO), has expanded its stability storage capabilities at its El Dorado Hills site in California. The new validated chambers increase storage capacity by 40% and are designed to meet rising demand for drug substance (DS) and drug product (DP) stability studies.
All chambers comply with current CGMP standards and support ICH storage conditions. Their proximity to the facility’s analytical testing labs enables streamlined workflows and faster turnaround times for clients. Additional chambers are scheduled for installation as part of a broader facility expansion planned for Q4 2025.
Shankar Sankaran, Executive Director of Analytical at SK pharmteco, stated, “Our expanded stability storage capacity, combined with our team’s extensive analytical development and validation experience for stability indicating methods, strengthens our ability to meet our clients’ evolving needs as their programs progress.”
The expansion is intended to support both standalone analytical projects and integrated contract manufacturing programmes. SK pharmteco continues to invest in infrastructure to meet client requirements across clinical and commercial development stages.
Stay ahead of trends and best practices
